^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Imfinzi (durvalumab)

    i
    Other names: MEDI4736, MEDI-4736, MEDI 4736
    Company:
    AstraZeneca
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    10h
    PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. (PubMed, J Hematol Oncol)
    PACIFIC-5 met its primary endpoint of improved PFS after either cCRT or sCRT. Follow-up for overall survival is ongoing.
    P3 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR expression
    |
    Imfinzi (durvalumab)
    14h
    COLUMBIA 1: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (clinicaltrials.gov)
    P1/2, N=61, Active, not recruiting, MedImmune LLC | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • oleclumab (MEDI9447)
    16h
    MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas (clinicaltrials.gov)
    P3, N=603, Active, not recruiting, Institut National de la Santé Et de la Recherche Médicale, France | Trial completion date: Oct 2025 --> Jan 2026
    Trial completion date • IO biomarker
    |
    Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Imfinzi (durvalumab) • lapatinib • Zykadia (ceritinib) • Tasigna (nilotinib) • Lytgobi (futibatinib) • Tabrecta (capmatinib) • Daurismo (glasdegib)
    18h
    Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. (PubMed, Ann Oncol)
    DUO-O met its primary PFS endpoints for first-line durvalumab plus carboplatin/paclitaxel and bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance versus carboplatin/paclitaxel and bevacizumab followed by bevacizumab in the non-tBRCAm HRD-positive and non-tBRCAm ITT populations. Further insight into long-term benefit is anticipated with additional follow-up.
    Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel
    1d
    A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, AstraZeneca | Trial completion date: Oct 2025 --> Mar 2026
    Trial completion date
    |
    Imfinzi (durvalumab) • ceralasertib (AZD6738)
    1d
    TAZMAN: Study of AZD2811 + Durvalumab in ES-SCLC (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • etoposide IV • barasertib-HQPA (AZD2811)
    4d
    A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=160, Not yet recruiting, Yonsei University
    New P1/2 trial • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Imfinzi (durvalumab) • venadaparib (NOV 1401)
    4d
    LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase classification: P1 --> P1/2 | N=40 --> 60 | Trial completion date: Dec 2026 --> May 2028 | Trial primary completion date: Jul 2025 --> May 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Imfinzi (durvalumab) • Tevimbra (tislelizumab-jsgr) • LK101
    4d
    A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation. (PubMed, Cancer Med)
    Our study demonstrated modest clinical benefits of D + O with ORR of 28.6% in subsets of heavily pretreated TNBC. Further detailed classification of DCs to understand the predictive role of DCs and prospective validation in a large cohort is required.
    P2 data • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • BRCA wild-type • BRCA mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    4d
    Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=21, Recruiting, Mary Feng, MD | Trial completion date: Feb 2027 --> Jul 2029 | Trial primary completion date: Feb 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    4d
    T Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma. (PubMed, Clin Cancer Res)
    These findings suggest that STRIDE and D+B have distinct, and potentially complementary, mechanisms of action in uHCC.
    PK/PD data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    6d
    CA-4948 in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Washington University School of Medicine | Trial completion date: Dec 2031 --> Apr 2032 | Initiation date: Oct 2025 --> Feb 2026 | Trial primary completion date: Jan 2030 --> May 2030
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • emavusertib (CA-4948)